Clinical Trial Detail

NCT ID NCT02147990
Title TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

lung non-small cell carcinoma

Therapies

Rociletinib

Age Groups: adult senior

Additional content available in CKB BOOST